• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Fan Hung-Shu

    4/1/26 3:10:21 PM ET
    $MENS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MENS alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Fan Hung-Shu

    (Last)(First)(Middle)
    23F-3, NO.95, SEC. 1, XINTAI 5TH RD.

    (Street)
    NEW TAIPEI CITYTAIWAN, PROVINCE OF CHINA221

    (City)(State)(Zip)

    TAIWAN

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/01/2026
    3. Issuer Name and Ticker or Trading Symbol
    Jyong Biotech Ltd. [ MENS ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    Fan Hung-Shu04/01/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $MENS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MENS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Hsu Ming Tsan

    3 - Jyong Biotech Ltd. (0001954488) (Issuer)

    4/1/26 3:43:46 PM ET
    $MENS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hsu Feng-Lin

    3 - Jyong Biotech Ltd. (0001954488) (Issuer)

    4/1/26 3:34:01 PM ET
    $MENS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hsu Feng-Lin

    3 - Jyong Biotech Ltd. (0001954488) (Issuer)

    4/1/26 3:20:48 PM ET
    $MENS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

    New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today provided an update on the plant-derived innovative drug MCS®-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Pioneering Plant-Based TherapeuticsDeveloped in Taiwan, MCS®-2 is the world's only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia (BPH). Jyo

    3/27/26 8:30:00 AM ET
    $MENS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

    - Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam.New Taipei City, Taiwan, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS

    2/12/26 8:30:00 AM ET
    $MENS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

    New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan. The results underscore MCS-8's previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in pros

    1/30/26 8:30:00 AM ET
    $MENS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MENS
    SEC Filings

    View All

    SEC Form 6-K filed by Jyong Biotech Ltd.

    6-K - Jyong Biotech Ltd. (0001954488) (Filer)

    2/6/26 4:31:03 PM ET
    $MENS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Jyong Biotech Ltd.

    6-K - Jyong Biotech Ltd. (0001954488) (Filer)

    1/9/26 4:30:01 PM ET
    $MENS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SP 15D2 filed by Jyong Biotech Ltd.

    SP 15D2 - Jyong Biotech Ltd. (0001954488) (Filer)

    6/30/25 4:05:45 PM ET
    $MENS
    Biotechnology: Pharmaceutical Preparations
    Health Care